Verrica Pharmaceuticals Inc (OQ:VRCA)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 10 N High St Ste 200
WEST CHESTER PA 19380-3014
Tel: N/A
IR: See website
Key People
Business Overview
Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.
Financial Overview
For the nine months ended 30 September 2018, Verrica Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $3M to $14.6M. Higher net loss reflects Research and development - Balancing val increase from $2.6M to $7.5M (expense), General and administrative - Balancing v increase from $356K to $4.6M (expense), Stock-Based Compensation in SG&A increase from $0K to $2.6M (expense).
Reporting Currency: U.S. Dollars
Enterprise value: $170.78M as of Sep 30, 2018
Annual revenue (TTM): $0.00M as of Sep 30, 2018
EBITDA (TTM): -$16.62M as of Sep 30, 2018
Net annual income (TTM): -$16.01M as of Sep 30, 2018
Free cash flow (TTM): -$12.94M as of Sep 30, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 25,696,371 as of Nov 2, 2018
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization